Критерии активности патологического процесса при рассеянном склерозе по результатам исследования регуляторных Т-клеток
Диссертация
В ЦНС происходит реактивация Т-клеток антиген-презентирующими клетками (АПК), в качестве которых выступают макрофаги и микроглия. Проникшие в ЦНС аутореактивные Т-клетки и вторично активированные макрофаги и микроглия также секретируют провоспалительные цитокины (интерферону (interferony — INFy), фактор некроза опухолиа (tumor necrosis factor — TNFa), лимфотоксин и др.), что еще в большей степени… Читать ещё >
Список литературы
- Airas L, Saraste M, Rinta S, Elovaara I. et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells // Clin Exp Immunol 2008. — V. 151(2). — p. 235−43.
- Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK. CD4+ T-regulatory cells: toward therapy for human diseases // Immunol Rev. — 2008. — V. 223. p. 391−421.
- Allan SE, Song-Zhao GX, Abraham T, McMurchy AN. et al. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 // Eur J Immunol. 2008. — V. 38(12). — p. 3282−9.
- Annunziato F, Cosmi L, Liotta F, Lazzeri E. et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes // J Exp Med. 2002. — V. 196(3). — p. 379−87.
- Arpinati M., Green C., Heimfeld S. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells // Blood. 2000. — V. 95. — p. 24 842 490.
- Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation // J Exp Med.- 1996. -V. 184(2).-p. 387−96.
- Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. II Ann Neurol. 2007. — V. 61(6). — p. 504−13.
- Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation IIJ Exp Med. 1999. — V. 190(7). — p. 995−1004.
- Astier AL, Hafler DA. Abnormal Trl differentiation in multiple sclerosis // J Neuroimmunol. 2007. -V. 191(1−2). — p. 70−8.
- Bacchetta R. et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations // J. Clin. Invest. 2006. — V. 116. — p. 1713— 1722.
- Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood // J Immunol. — 2001. V. 167(3). — p. 1245−53.
- Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease // Immunol Rev. 2006. — V. 212. — p. 203−16.
- Balandina A, Lecart S, Dartevelle P, Saoudi A. et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis // Blood. 2005. — V. 105(2). — p. 735−41.
- Battaglia M. et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients // J. Immunol. 2006. — V. 177. — p. 8338−8347.
- Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity // Nature. 2002. — V. 420(6915). — p. 502−7.
- Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells // Nature. — ji2006.-V. 441 (7090).-p. 235−238.
- Bettini M, Vignali D.A. Regulatory T cells and inhibitory cytokines in autoimmunity I I Curr Opin Immunol. — 2009. V. 21(6). — p. 612−8.
- Beyersdorf N, Gaupp S, Balbach K, Schmidt J. et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy ofexperimental autoimmune encephalomyelitis // J Exp Med. 2005. — V.02(3). -p. 445−55.
- Bonomo A, Kehn PJ, Payer E, Rizzo L. et al. Pathogenesis of post-thymectomy autoimmunity. Role of syngeneic MLR-reactive T cells // J Immunol. 1995. — V. 154(12). — p. 6602−11.
- Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A. et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression // Blood. 2007. — V. 110(4). — p. 1225−32.
- Braitch M, Harikrishnan S, Robins RA, Nichols C. et al. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis // Acta Neurol Scand. 2009. — V. 119(4). — p. 239−45.
- Broux B. et al. Haplotype 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants // Genes Immun. 2010. — doi:10.1038/gene.2009.106.
- Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J. et al. Shortlived plasma blasts are the main B cell effector subset during the course of multiple sclerosis//Brain. 2005. — V. 128.-p. 1667−1676.
- Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation // N Engl J Med. 2006. — V. 354. — p. 610−621.
- Chen W, Jin W, Hardegen N, Lei KJ. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 // J Exp Med. 2003. — V. 198(12). — p. 1875−86.
- Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis // Int Rev Neurobiol. 2007. — V. 79. — p. 43−72.
- Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner // J Immunol. 2009. — V. 182(10).-p. 6121−8.
- Collison LW, Workman CJ, Kuo TT, Boyd K. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function // Nature. 2007. — V. 450(7169). -p. 566−9.
- Compston A, Coles A. Multiple sclerosis // Lancet. 2008. — V. 372. — p. 1502−17.
- Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis // Neuroimaging Clin N Am. 2008. — V.18(4). — p. 589−622.
- Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A. et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis // Proc Natl Acad Sci US A.- 2004. V. 101. — p. 1 106 411 069.
- Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometic assay // Blood. 2004. — V. 103. — p. 4222−31.
- Darrasse-Jeze G, Deroubaix S, Mouquet H. et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo // J Exp Med. 2009. — V. 206(9).-p. 1853−62.
- De Jager PL, Baecher-Allan C, Maier LM. et al. The role of the CD58 locus in multiple sclerosis // Proc Natl Acad Sci USA. 2009. — V. 106(13).-p. 52 649.
- Deaglio S, Dwyer KM, Gao W, Friedman D. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression // J Exp Med. 2007. — V. 204(6). — p. 1257−65.
- Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases // Immunology. — 2006. V. 117(3).-p. 289−300.
- Delgado S. and Sheremata W.A. The role of CD4+ T-cells in the development of MS II Neurol Res 2006. — V. 28. — p. 245−249.
- Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis // Neurology. 2007. — V. 29−68(22 Suppl 3). — p. SI3−21- discussion S43−54.
- Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1 -like regulatory T cells corrected. // J Exp Med.-2W2.-V. 196(2).-p. 247−53.
- Dieckmann D, Plottner H, Berchtold S, Berger T. et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood // J Exp Med. 2001. — V. 193(11).-p. 1303−10.
- Ding Q, Li XD. Neural pathway for fever generation // Neurosci Bull. -2006.-V. 22(6).-p. 350−4.
- Dong C, Flavell RA. Cell fate decision: T-helper 1 and 2 subsets in immune responses // Arthritis Res. 2000. — V. 2. — p. 179−188.
- Drakesmith H., Chain B., Beverley p. How can dendritic cells cause autoimmune disease? // Immunol. Today. 2000. — V. 21. — p. 214−217.
- Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis // Neurology. 2007. — V. 68(22 Suppl 3):S22−31- discussion S43−54.
- Ebers G. Disease evaluation in multiple sclerosis 2006 // J. Neurol. 2006. -V.253 (6).-p. 3−8.
- Ebers GC. Environmental factors and multiple sclerosis // Lancet Neurol -2008.-V. 7(3).-p. 268−277.
- Ephrem A, Chamat S, Miquel C, Fisson S. et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis // Blood. 2008. — V. 111(2). — p. 715−22.
- Fahlen L, Read S, Gorelik L, Hurst SD. et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells // J Exp Med. -2005. V. 201(5). — p. 737−46.
- Fantini MC, Becker C, Monteleone G, Pallone F. et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. // J Immunol. 2004. — V. 172(9). — p. 5149−53.
- Feger U et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation // Blood. 2007. -V. 110. — p.568−577.
- Filippi M, Rocca MA. MRI aspects of the «inflammatory phase» of multiple sclerosis I I Neurol Sci. 2003. — V. 24. Suppl 5: S275−8.
- Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N. et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis // Clin Exp Immunol. -2010.-V. 162(1).-p. 1−11.
- Fletcher JM, Lonergan R, Costelloe L, Kinsella K. et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Thl7 cells and are impaired in multiple sclerosis // J Immunol. — 2009. — V. 183(11).-p. 7602−10.
- Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells // Nat Immunol. 2003. — V. 4(4).-p. 330−6.
- Fourcade J, Sun Z, Kudela P, Janjic B. et al. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire // J Immunol. — 2010. — V. 184(12).-p. 6709−18.
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis the plaque and its pathogenesis // N Engl J Med. — 2006. — V. 354. — p. 942−55.
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis // N Engl J Med. 2006. — V. 354(9). — p. 942−55.
- Fu S, Zhang N, Yopp AC, Chen D, Mao M. et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 precursors // Am J Transplant. — 2004. -V. 4(10).-p. 1614−27.
- Gartner D, Hoff H, Gimsa U, Burmester GR. et al. CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression // JNeuroimmunol. 2006. — V. 172(1−2). — p. 73−84.
- Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes // Immunology. 1970. — V. 18(5). — p. 723−37.
- Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes // Immunology. 1970. — V. 18(5). — p. 723−37.
- Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells // J Immunol. — 2008. — V. 1−181(3). p. 1798−805.
- Gold R., Lunder F. Interleukin-17-extended features of a key player in multiple sclerosis. Am II J. Pathol. 2008. — 172 (1). — p. 8−10.
- Gotter J, Kyewski B. Regulating self-tolerance by deregulating gene expression // Curr Opin Immunol. — 2004. — V. 16(6). p. 741−5.
- Grindebacke H, Wing K, Andersson AC, Suri-Payer E. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergies during birch pollen season // Clin Exp Allergy. 2004. — V. 34(9). — p. 1364−72.
- Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis // Eur J Immunol. 2005.-V. 35.-p. 3343−52.
- Handel A.E., Giovannono G., Ebers G.E. and Ramagopalan S.V. Environmental factors and their timing in adult-onset multiple sclerosis // Nat Rev Neurol -2010. -V. 6.-p. 156−166.
- Hara M, Kingsley CI, Niimi M, Read S. et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo // J Immunol. -2001.-V. 15. 166(6).-p. 3789−96.
- Hemmer B., Archelos J.J. and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis // Nat Rev Neurosci. 2002. — V. 3. -p. 291−301.
- Hoffmann, P. et al. Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells II Blood. 2004. — V. 104. — p. 895−903.
- Hofsretter H.H. et al. Ibrahim S.M., Koczan D. et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis // Cell Immunol.- 2005.-V. 237 (2).-p. 123−130.
- Hofstetter H.H., Gold R., Hartung H-P. Th 17 cells in MS and experimental autoimmune encephalomyelitis // Int. MS J. 2009. — V. 16. — p. 12−18.
- Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease II Neurology. 2007. -V. 68(22 Suppl 3):S58−63- discussion S91−6.
- Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis // Curr Opin Neurol- 2001. -V. 14(3).-p. 299−304.
- Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells II Adv Immunol. 2003. — V. 81. — p. 331 -71.
- Huan J. Decreased FOXP3 levels in multiple sclerosis patients // J N euros ci Res. 2005. — V. 81. — p. 45−52.
- Hug A. et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis // J. Immunol. 2003. — V. 171. — p. 432 437.
- Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis // J Exp Med. 2001. — V. 194.-p. 669−76.
- Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation // Annu Rev Immunol. 2009. — V. 27. — p. 313−38.
- Jian H, Shen X, Liu I, Semenov M, He X, Wang XF. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-betal-induced proliferation of bone marrow-derived adult human mesenchymal stem cells // Genes Dev. 2006. — V.20(6). — p. 666−74.
- Jiang S, Lechler RI, He XS, Huang JF. Regulatory T cells and transplantation tolerance // Hum Immunol. 2006. — V. 67(10). — p. 765−76.
- Joetham A, Takeda K, Taube C, Miyahara N. et al. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta // J Immunol. 2007. — V. 178(3).-p. 1433−42.
- Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells // J Exp Med. 2002. — V. 196(2). — p. 25 560.
- Jonuleit H, Schmitt E, Stassen M, Tuettenberg A. et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood // J Exp Med. 2001. — V. 193(11). — p. 1285−94.
- Juszczak M, Glabiriski A. Thl7 cells in the pathogenesis of multiple sclerosis // PostepyHigMedDosw.- 2009. V. 63. — p. 492−501.
- Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights // Curr.Opin.Neurol. 2006. — V. 19(3). — p. 248−254.
- Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD. et al. CTLA-4: a negative regulator of autoimmune disease // J Exp Med. 1996. — V. 184(2). — p. 783−8.
- Kerschensteiner M, Misgeld T. Cellular imaging in the nervous system // Dtsch Med Wochenschr. 2007. — V. 132(47). — p. 2529−33.
- Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses // J Immunol. — 2002. V. 168(3).-p. 1080−6.
- Kohm AP, Carpentier PA, Miller SD. Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells // Novartis Found Symp. 2003. — V. 252. — p. 45−52- discussion 52−4, 106−14.
- Korn T, Anderson AC, Bettelli E, Oukka M. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis // J Neuroimmunol. 2007. — V. 191(1−2). — p. 51−60.
- Korn T, Mitsdoerffer M, Croxford AL. et al. IL-6 controls Thl7 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells // Proc Nad Acad Sci USA.- 2008. V. 105(47).-p. 18 460−5.
- Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease // Am J Pathol.- 1993. -V. 143(1).-p. 3−9.
- Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis // Brain. 2005. — V. 128(Pt 11). — p. 2705−2712.
- Lassmann, H., Brack, W. and Lucchinetti, C.F. ().The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007. — 17: 210−218.
- Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells // Int Arch Allergy Immunol. 2002 Dec-129(4):263−76.
- Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta 1 controls T cell tolerance and regulates Thl- and Thl7-cell differentiation // Immunity. 2007. -V. 26(5). — p. 579−91.
- Ling EM, Smith T, Nguyen XD, Pridgeon C. et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease // Lancet. 2004. — V. 21−363(9409). — p. 60 815.
- Lock C, Hermans G, Pedotti R, et al. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis // Nat Med. 2002. — V. 8. — p. 500−8.
- Lu L, Zhou X, Wang J, Zheng SG, Horwitz DA. Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-P and retinoic acid // PLoS One. 2010. — V. 5(12). — p. el5150.
- Luhder F, Hoglund P, Allison JP, Benoist C. et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes // J Exp Med.- 1998.-V. 187(3).-p. 427−32.
- Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus // Adv Exp Med Biol. 2007. — V. 601. — p. 113−9.1.l
- Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor II Immunity. 2006. — V. 25(3). — p. 441−54.
- Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S. et al. IL-10 suppressor activity and ex vivo Trl cell function are impaired in multiple sclerosis II Eur J Immunol. 2008. — V. 38(2). — p. 576−86.
- Matejuk A, Dwyer J, Hopke C, Vandenbark AA. et al. Opposing roles for TGF-betal and TGF-beta3 isoforms in experimental autoimmune encephalomyelitis // Cytokine. 2004. — V. 25(2). — p. 45−51.
- Matsumoto Y, Sakuma H, Kohyama K, Park IK. Paralysis of CD4(+)CD25(+) regulatory T cell response in chronic autoimmune encephalomyelitis // JNeuroimmunol. 2007. — V. 187(1−2). — p. 44−54.
- McDole J, Johnson A. J, and Pirko I. The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis // Neurol Res. 2006. — V. 28.-p. 256−261.
- McDonald WI, Compston A, Edan G et al. Recommended diagnostic criateria for multiple sclerosis: guidelines for the International Panel on duagnosis of multiple sclerosis // Ann Neurol. — 2001. — V. 50. — p. 121−7.
- McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system // J Immunol. 2005. — V. 175(5). — p. 3025−32.
- McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Thl/Th2 paradigm in immunity to infectious diseases // Trends Immunol. — 2002.-V. 23(9).-p. 450−5.
- Miller A, Eninia G, Metra M, Platkais A, Kukaine R. Adhesive molecules as immunologic markers of activity of multiple sclerosis // Zh Nevrol Psikhiatr Im S SKorsakova. -2003. -V. 103(1). p. 35−8.
- Mills KH. Regulatory T cells: friend or foe in immunity to infection? // Nat Rev Immunol.- 2004. -V. 4(11). p. 841−55.
- Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified // Arthr Rheum. — 2007. V. 56. — p. 21 115.
- Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine II Immunol Rev. 2008. -V. 226. — p. 205−18.
- Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta // J. Exp. Med. 2001. — V. 194. -p. 629−644.
- Neuhaus O., Archelos J.J., Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection // TRENDS Pharmacol. Sci. -2003.- V. 24 (3). — p. 131−138.
- Noseworthy JH, et al. Multiple sclerosis // N. Engl. J. Med. 2000. — V. 343(13).-p. 938−952.
- Ochoa-Reparaz J, Riccardi C, Rynda A, Jun S. et al. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis // J Immunol. — 2007. — V. 178(3).-p. 1791−9.
- O’Connor RA, Malpass KH, Anderton SM. -The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells // J Immunol 2007. — V. 179(2). — p. 958−66.
- O’Neill DW. Dendritic cells and T cells in immunotherapy // J Drugs Dermatol- 2010. -V. 9(11).-p. 1383−92.
- Pagani E, Rocca MA, Gallo A. et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype // AJNR Am JNeuroradiol. ~ 2005. V. — p. 26(2):341−6.
- Paul WE, Seder RA. Lymphocyte responses and cytokines I I Cell 1994. -V. 28- 76(2).-p. 241−51.
- Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease // Proc Natl Acad Sci U S A. -2004.-V. 101(28).-p. 10 398−403.
- Perrin PJ, Maldonado JH, Davis TA, June CH. et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis // J Immunol 1996.-V. 157(4).-p. 1333−6.
- Peters JH, Hilbrands LB, Koenen HJ, Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy // PLoS One. 2008. — V. 3(5). — p. e2233.
- Peters JH, Preijers FW, Woestenenk R. et al. Clinical grade Treg: GMP isolation, improvement of purity by CD 127 Depletion, Treg expansion, and Treg cryopreservation // PLoS One. 2008. — V. 3(9). — p. e3161.
- Peterson P, Org T, Rebane A. Transcriptional regulation by AIRE: molecular mechanisms of central tolerance // Nat Rev Immunol — 2008. V. 8(12).-p. 948−57.
- Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance // Semin Immunol- 2004.-V. 16(2).-p. 81−8.
- Pohlers D, Beyer A, Koczan D, Wilhelm T. et al. Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts // Arthritis Res Ther. 2007. — V. 9(3). — p. R59.
- Poser CM., Paty D.W., Scheinberg L.C. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols // Ann. Neurol. 1983. — V. 13.-p. 227−231.
- Probst-Kepper M, Kroger A, Garritsen HS, Buer J. Perspectives on Regulatory T Cell Therapies // Transfus Med Hemother. 2009. — V. 36(5). — p. 302−308.
- Ramagopalan S.V., Dyment D.A. and Ebers G.C. Environmental factors and their timing in adult-onset multiple sclerosis // Trends Neurosci. 2009. — V. 649. -p. 1−8.
- Ramsdell F, Ziegler SF. Transcription factors in autoimmunity // Curr Opin Immunol. 2003. — V. 15(6). — p. 718−24.
- Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning // Immunity. — 2009. V. 30(5). — p. 65 665.
- Romagnani S. Human Thl7 cells // Arthr Res Ther. 2008. — V. 10. — p. 206.
- Roncarolo MG, Battaglia M, Gregori S. The role of interleukin 10 in the control of autoimmunity // J Autoimmun. — 2003. V. 20(4). — p. 269−72.
- Royal W., Ill et al. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis // J. Neuroimmunol. 2009. — V. 213. — p. 135−141.
- Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene // Cell. — 1993. -Y. 75(2).-p. 253−61.
- Saresella M, Marventano I, Longhi R, Lissoni F. et al. CD4+CD25+FoxP3+PDl- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy // FASEB J. — 2008. -V. 22(10).-p. 3500−8.
- Saurav Brahmachari and Kalipada Pahan. Myelin Basic Protein Priming Reduces the Expression of Foxp3 in T Cells via Nitric Oxide // J Immunol. -2010. V. 184. -p. 1799−1809.
- Selvaraj RK, Geiger TL. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance // J Immunol. — 2008. — V. 180(5).-p. 2830−8.
- Shevach EM, McHugh RS, Thornton AM, Piccirillo C. et al. Control of autoimmunity by regulatory T cells // Adv Exp Med Biol. 2001. — V. 490. — p. 21−32.
- Shull MM, Ormsby I, Kier AB, Pawlowski S. et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease // Nature. 1992. — V. 359(6397). — p. 693−9.
- Smolders, J. et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis // PLoS. 2009. — V. One 4. — p. e6635.
- Sospedra M. and Martin R. Immunology of multiple sclerosis // Annu Rev Immunol- 2005.-V. 23. p. 683−747.
- Stadelmann C, Albert M, Wegner C, Brack W. Cortical pathology in multiple sclerosis // Curr Opin Neurol. 2008. — V. 21(3). — p. 229−34.
- Sugiyama H, Gyulai R, Toichi E, Garaczi E. et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation // J Immunol. -2005.-V. 174(1).-p. 164−73.
- Takahashi T, Tagami T, Yamazaki S, Uede T. et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 // J Exp Med. 2000. -V. 192(2).-p. 303−10.
- Thewissen M, and Stinissen P, New concepts on the pathogenesis of autoimmune diseases: a role for immune homeostasis, immunoregulation, and immunosenescence // Crit. Rev. Immunol. — 2008. V. 28. — p. 363−376.
- Tivol EA, Borriello F, Schweitzer AN, Lynch WP. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 // Immunity. 1995. — V. 3(5).-p. 541−7.
- Toda A, Piccirillo CA. Development and function of naturally occurring CD4+CD25+ regulatory T cells // JLeukoc Biol. 2006. — V. 80(3). — p. 458−70.
- Torkildsen O., Nyland H., Myrmel H., Myhr K.M. Epstein-Barr virus reactivation and multiple sclerosis // Eur. J. Neurol. 2008. — V. 15 (1). — p. 106 108.
- Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y Impact of multiple sclerosis relapses on progression diminishes with time // Neurology. — 2009.-V. 73(20).-p. 1616−23.
- Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation // Trends Pharmacol Sci. 2006. — V, 27.-p. 48−55.
- Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress // BioDrugs. 2008. — V. 22(4). — p. 265−73.
- Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis // Trends Mol Med. 2010. — V. 16(2). — p. 5868.
- Venken K, Thewissen M, Hellings N, Somers V. et al. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of autoantigen specific and polyclonal T cell responses // J Immunol Methods. 2007. -V. 322(1−2).-p. 1−11.
- Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid-Grendelmeier P. et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin // J Allergy Clin Immunol. 2006. — V. 117(1). — p. 176−83.
- Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis // J Exp Med. 2004. — V. 199.-p. 971−9.
- Vignali DA, Collison LW, Workman CJ. How regulatory T cells work // Nat Rev Immunol. 2008. — V. 8(7). — p. 523−32.
- Walker MR, Kasprowicz DJ, Gersuk VH, Benard A. et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells IIJ Clin Invest. 2003. — V. 112(9). — p. 1437−43.
- Waterhouse P, Penninger JM, Timms E, Wakeham A. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 // Science. 1995. — V. 270(5238). — p. 985−8.
- Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages // Annu Rev Immunol. ~ 2007.-V. 25.-p. 821−52.
- Wilkins A, Scolding N. Protecting axons in multiple sclerosis // Mult Scler. 2008. — V. 14(8).-p. 1013−25.
- Wraith DC, Nicolson KS, Whitley NT. Regulatory CD4+ T cells and the control of autoimmune disease // Curr Opin Immunol. 2004. — V.16(6). — p. 695−701.
- Xu YQ, Gao YD, Yang J, Guo W. A defect of CD4+CD25+ regulatory T cells in inducing interleukin-10 production from CD4+ T cells under CD46 costimulation in asthma patients // J Asthma. — 2010. V. 47(4). — p. 367−73.
- Xystrakis E, Boswell SE, Hawrylowicz CM. T regulatory cells and the control of allergic disease // Expert Opin Biol Ther. 2006. — V. 6(2). — p. 12 133.
- Yong V.W. Differential mechanisms of action of interferon-p and glatiramer acetate in MS II Neurology. 2002. — V. 59. — p. 802−808.
- Zang YC, Li S, Rivera VM, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis // J Immunol. 2004. — V. 172. — p. 5120−7.
- Zhang X, Reddy J, Ochi H, Frenkel D. et al. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells // Int Immunol. 2006. — V. 18(4). — p. 495−503.
- Zouali, M. В lymphocytes—chief players and therapeutic targets in autoimmune diseases/У Front Biosci. 2008.-V. 13.-p. 4852−4861.
- Воробьев A.A., Быковская С. Ю., Пашков Е. П., Быков А. С. Роль клеток-регуляторов CD4+CD25+ в развитии хронических инфекционных заболеваний // Вести РАМН. 2006. — № 9−10. — с. 24−9
- Гусев Е.И. Рассеянный склероз/ Е. И. Гусев, T.JI. Демина, А. Н. Бойко — М.: Нефть и газ, 1997. 463 с. 41 .Гусев Е. И. Рассеянный склероз: от изучения патогенеза к новым методам лечения/ Е. И. Гусев, А. Н. Бойко. М ., — 2001. С. 19−55.
- Гусев Е.И., Бойко А. Н. Рассеянный склероз: достижения десятилетия // Журн неврол u ncuxuam. — 2007. (Спец. выпуск «Рассеянный склероз») № 4.-с. 4−13.
- Гусев Е.И., Бойко А. Н., Завалишин И. А. Эпидемиологическое исследование рассеянного склероза. Методические рекомендации МЗ РФ№ 2003/82, Москва 2003, 80с.
- Гусев Е.И., Завалишин И. А., Бойко А. Н. Рассеянный склероз и другие демиелинизирующие заболевания М: Миклош, 2004. 540 с.
- Завалишин И.А., Головкин В. И. Рассеянный склероз. Избранные вопросы теории и практики.- М., 2000. 637 с.
- И. А. Завалишин, А. В. Переседова. Современные представления о патогенезе и лечении рассеянного склероза // Атмосфера. Нервные болезни. -2005.-№ 2.-с. 11−16.
- Кичерова О.А. и др. Рассеянный склероз / О. А. Кичерова, Л. И. Рейхерт, С. М. Быченко. Тюмень: Сити-пресс. -2007. — 151с.
- Корсупский И.А., Румянцев А. Г., Быковская С. Н. Роль регуляторных Т-клеток CD4+CD25+ и мезенхимальных стволовых клеток костного мозгав подавлении реакции трансплантат против хозяина // Онкогематология. — 2008.-№ 3.-с. 45−51.
- Меркулов Ю. А., Завалишин И. А., Меркулова Д. М. Роль аксонопатии в механизмах развития демиелинизирующих процессов в центральной и периферической нервной системе // Журн. неврологии и психиатрии им. С. С. Корсакова. 2007. — № 3. — с. 26−30.
- Насонов Е.Л., Быковская С. Н. Т-регуляторные клетки при аутоиммунных ревматических заболеваниях // Вестн РАМН. 2006. — № 9−10.-с. 74−82.